AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Set up an RSS feed
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Brown University Geriatric Psychopharmacology Update back issues
|
|
Decreased delirium in elderly patients treated with melatonin.(What's New in Research)(Clinical report)
February 1, 2011... Supplementation with nightly melatonin significantly reduced the proportion of elderly patients who experienced delirium, compared with patients who received placebo, in a randomized controlled trial. Lead study author Tareef Al-Aama, M.D., and colleagues believe the trial is the first to...
Problems ensue from discontinuing memantine in residents with AD.(What's New in Research)
February 1, 2011... Within a few months of discontinuing memantine, nursing home residents with Alzheimer's disease (AD) experienced significant worsening of dementia-associated symptoms and loss of body weight, according to the results of a retrospective chart review. Cognition and mood were particularly...
Bupropion-induced Parkinsonism and dystonia.(Adverse Events)
February 1, 2011... Bupropion (Wellbutrin, Zyban) is an antidepressant of the aminoketone class. Its antidepressant activity is believed to be primarily via inhibition of norepinephrine uptake, although it has also been reported to be a weak inhibitor of dopamine and serotonin reuptake. The common adverse...
Timing of hormone replacement therapy and dementia: The critical window theory.(Hormone Therapy)(Clinical report)
February 1, 2011... Rachel A. Whitmer and colleagues have published a study that adds important evidence to the research examining what is referred to as the "critical window" theory, which posits that hormone replacement therapy (HT) may be most protective of neurocognition when taken only in the perimenopausal...
Patients safely switch from donepezil to rivastigmine transdermal patch.(Alzheimer's Disease)
February 1, 2011... Whether immediately switching patients from oral donepezil to the rivastigmine transdermal patch or discontinuing donepezil and waiting a week before switching, both strategies appear to be safe and generate no significant deterioration in cognition, behavior, and global functioning in patients...